A multicenter, prospective cohort study involving 196 patients with NSCLC, melanoma, RCC, or head and neck cancer reported that those who received antibiotics prior to PD-1/PD-L1 antibody treatment had poorer responses and OS 299. The gene discussed is PDCD1; the disease is renal cell carcinoma.